| Document |
Document Title |
|
WO/2005/021517A1 |
The invention relates to a method of preparing urethane-protected N-carboxyanhydrides of alpha amino acids. The inventive method enables the synthesis of urethane-protected N-carboxyanhydrides of alpha amino acids in the presence of a ca...
|
|
WO/2005/020897A2 |
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8...
|
|
WO/2005/019174A1 |
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...
|
|
WO/2005/019214A1 |
Compounds of formula (I) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of fo...
|
|
WO/2005/019151A1 |
The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator acti...
|
|
WO/2005/019213A1 |
The present invention provides antibacterial agents having the formulae (I) and (II) as described herein.
|
|
WO/2005/019212A1 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/019211A2 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at le...
|
|
WO/2005/019184A1 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/016338A1 |
The use of a 5HT2B receptor antagonist for the manufacture of a medicament for the treatment of congestive heart failure.
|
|
WO/2005/016267A2 |
The present invention relates to compounds of the Formula (I), wherein R3, R5, R6, R7, and Z, and other variables enumerated under one or more of R3, R5, R6, R7, and Z, are as defined. Compounds of the Formula (I) have activity inhibitin...
|
|
WO/2005/016866A2 |
The present invention is to provide a method for producing the desired optically active β-amino acid derivatives of high optical purities in high yields, without requiring a step of deprotection. More particularly, the present invention...
|
|
WO/2005/016384A1 |
It is intended to provide a compound having a high specificity for amyloid β protein which is usable in diagnosing a disease with amyloid β protein deposit, a staining agent specific for amyloid β protein and treating and preventing a...
|
|
WO/2005/016888A1 |
It is intended to provide a compound highly specific to amyloid β-protein to be used in diagnosing diseases with amyloid β-protein accumulation, a staining agent specific to amyloid β-protein and treating and preventing diseases with ...
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/016344A1 |
This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1 to R5 are defined in the description, and to processes for the preparation thereof, intermediates used ...
|
|
WO/2005/013914A2 |
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...
|
|
WO/2005/014563A1 |
The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerativ...
|
|
WO/2005/012263A1 |
Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor.
|
|
WO/2005/012221A1 |
A compound represented by the general formula (I): (wherein rings A, B, and D each independently represents an optionally substituted cyclic group; W represents a spacer whose main chain has 1 to 8 atoms; X represents a spacer whose main...
|
|
WO/2005/012296A1 |
Leukotriene A4 hydrolase (LTA4H) inhibitors of formula I, compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated wi...
|
|
WO/2005/012228A1 |
The invention relates to novel o ptical recording materials that comprise specific and in some cases novel diketone enamines or metal chelates thereof and that have excellent recording and playback quality especially ata wavelength of 35...
|
|
WO/2005/012270A2 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of biaryl heterocyclic amines, amides, and sulfur-...
|
|
WO/2005/012271A2 |
The present invention relates to processes for the preparation of biaryl oxazolidinones. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
|
|
WO/2005/009981A1 |
The invention relates to surface-functionalized support materials, respectively comprising a polymer surface and at least one linker compound which is bonded to said surface in a covalent manner, as well as to the production and use ther...
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/009941A1 |
The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.
|
|
WO/2005/009951A2 |
The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory a...
|
|
WO/2005/009998A1 |
This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers...
|
|
WO/2005/007616A1 |
The present invention relates to diphenylamino ketone derivatives, pharmaceutical compositions and methods of use thereof.
|
|
WO/2005/005399A1 |
This invention relates to new oxazolidin,41-es having a C' cl ropyl moiety, which are effective against aerobic and anerobic pathogen I esistant staphylococci, streptococci and enterococci, Bacteroides s Cl' idia spp. species, as well as...
|
|
WO/2005/004810A2 |
N-aryl arylsulfonamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
|
|
WO/2005/005398A2 |
This invention relates to new oxazolidinones having a cyclopropyl moiety, which are effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. s...
|
|
WO/2005/005420A1 |
This invention relates to new oxazolidinones, having a cyclopropyl moiety, which are effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. ...
|
|
WO/2005/005456A2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
WO/2005/002514A2 |
Compounds inhibiting phosphatidylinositol 3-kinase (PI 3-K) activities and methods of preparing and using thereof in treating diseases are disclosed. Compounds inhibiting PI 3-K activity and methods of using PI 3-K inhibitory compounds t...
|
|
WO/2005/000824A1 |
Novel azolidine derivatives of the formula (I) wherein R1 represents halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, haloalkylthio or haloalkylene-dioxy, m represents 0, 1, 2, 3, 4 or 5, the R1 substituents are identical or different each...
|
|
WO/2005/000852A2 |
The invention relates to a product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent for simultaneous, separate or staggered therapeutic use during treatment for cancer. According to th...
|
|
WO2004101573A9 |
The invention relates to a method of synthesising heterocyclic compounds. The invention is characterised in that it consists in opening a compound having formula (I), wherein: - X represents NH, O, S or a N-p group, p being a protective ...
|
|
WO/2005/000309A2 |
Compounds of the formulae (I) and (II), and pharmaceutically acceptable salts thereof, are found to be inhibitors of sensory neurone specific (SNS) sodium channels. They are therefore useful as analgesic and neuroprotective agents. Formu...
|
|
WO/2005/000298A2 |
Provided are aminoaryl substituted 5-membered heterocycle-based p38 kinase, including p38alfa and p38beta. Pharmaceutical compositions containing the compounds are also provided. Method of use of the compounds and compositions are also p...
|
|
WO/2005/000406A2 |
Methods of treating or preventing an amyloid-related disease in a subject by administering to a subject a therapeutic amount of a compound of the invention are described. Also included are methods for inhibiting epileptogenesis in a subj...
|
|
WO/2004/113308A1 |
The invention relates to a method for producing an aryl oxazolyl ethyl alcohol of formula (I), which constitutes an intermediate stage in the production of medicaments. Said method comprises the reduction of a compound of formula (II) us...
|
|
WO/2004/110986A1 |
A compound which functions to inhibit capsaicin receptor VR1 activation and is useful as a therapeutic agent for, e.g., various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, and bladder diseases inclu...
|
|
WO/2004/111020A1 |
This invention relates to compounds of the formula (I); wherein X, Y, R1 to R11 and n are as defined in the description, and all enantiomers; and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to p...
|
|
WO/2004/110439A1 |
This invention relates to novel biologically active polyene oxazoles of Formula (I), their pharmaceutically acceptable salts and derivatives, and to methods of obtaining them. One method for obtaining the compounds is by cultivation of S...
|
|
WO/2004/108694A1 |
Compounds of the general formula (I) are useful as fungicides wherein Het is a 5- or 6- linked group of the formula (a) or (b), and the variables are as defined in the claims.
|
|
WO/2004/108133A2 |
The present invention relates to compounds useful as modulators of the vanilloid receptor, and also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the ...
|
|
WO/2004/108685A1 |
Aryl-heteroaromatic products, compositions containing same and use thereof. The invention provides new chemical compounds, in particular new aryl-heteroaromatic products, compositions containing same and use thereof as drugs, in particul...
|
|
WO/2004/108661A1 |
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is dir...
|
